UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.
Read original at benzingaStocks · News reference
TransMedics Group shares are trading lower after the company reported mixed Q2 financial results. The stock initially traded higher yesterday after the market closed, but it has since reversed.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 11:55 AM
- Checked
- Aug 5, 2026, 11:55 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why TransMedics Stock Is Sinking Today
TransMedics stock fell 8% after Q2 earnings showed 21% sales growth but adjusted net income dropped more than 50% due to reinvestment in new kidney organ care systems and manufacturing. Despite the decline, the analyst remains bullish on the stock, citing upcoming clinical trials for heart and lung systems, a new kidney OCS in development, and European expansion opportunities.
Read original at the-motley-foolPiper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
Read original at benzingaSpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
Read original at benzinga